1. Heparin does not improve myocardial glucose metabolism suppression in [18 F]FDG PET/CT in patients with low β-hydroxybutyrate level
- Author
-
Suvi Hartikainen, Ville Vepsäläinen, Tiina Laitinen, Marja Hedman, Tomi Laitinen, and Tuomo Tompuri
- Subjects
Myocardial inflammation ,Beta-hydroxybutyrate ,BHB ,FDG-PET ,Glucose metabolism ,Myocardium ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Inadequate myocardial glucose metabolism suppression (GMS) can hamper interpretation of cardiac [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET/CT). Use of β-hydroxybutyrate (BHB) measurement before [18F]FDG injection has been proposed for predicting adequate GMS. However, limited information is available on BHB measurement in guiding preparations for [18F]FDG-PET/CT. The purpose of this study was to evaluate if point-of-care measured BHB is useful in guiding heparin premedication for cardiac [18F]FDG-PET/CT. Results 155 patients (82 male) had followed a high-fat, low-carbohydrate diet and fasted for at least twelve hours. For the first 63 patients, BHB was measured, but it was not used to guide premedication. For the subsequent 92 patients, heparin 50 IU/kg was injected intravenously 15–20 min before [18F]FDG injection if the BHB level was low (
- Published
- 2024
- Full Text
- View/download PDF